IL2 is also used as an adjuvant in the treatment of patients with melanoma, advanced colorectal cancer or ovarian cancer with autologous dendritic cells stimulated by autologous tumor lysate (Baek et al., 2015; Greene et al., 2016; Liu et al., 2016), as well as in the treatment with viral vaccines (Oudard et al., 2011). This evidence concerns the gene IL2 and melanoma.